PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
RNA sequencing (RNAseq)
antibody–drug conjugate
biomarkers, bladder cancer
nectin‐4
programmed death ligand‐1 (PD‐L1)
whole‐exome sequencing
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
revised:
07
05
2024
received:
16
02
2024
accepted:
17
05
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
Bladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin-4 and programmed death ligand-1 (PD-L1) has been reported in BCDD. Importantly, nectin-4 expression in bladder cancer is associated with response to enfortumab vedotin, and PD-L1 expression is associated with responses to immune checkpoint inhibitors (ICIs). The authors conducted a retrospective review identifying 117 patients with advanced or metastatic BCDD who were treated at Winship Cancer Institute from 2011 to 2021. They performed immunohistochemistry staining for nectin-4 and PD-L1 expression by histologic subtype as well as genomic analysis of these patients, including RNA sequencing, whole-exome sequencing, and fusion detection analysis as well as a subgroup genomic analysis of patients with BCDD who received ICIs. The results indicated that nectin-4 expression was highest in the groups who had the squamous and plasmacytoid subtypes, whereas the group that had the sarcomatoid subtype (70.8%) had the highest proportion of PD-L1-positive patients. Genomic analysis yielded several key findings, including a 50% RB1 mutation rate in patients who had small cell BCDD, targetable PIK3CA mutations across multiple subtypes of BCDD, and significantly higher expression of TEC in responders to ICIs. In this study, the authors identified clinically relevant data on nectin-4 and PD-L1 expression in patients with rare bladder tumors. They also identified several novel findings in the genomic analysis that highlight the role of precision medicine in this population of patients. Larger, prospective studies are needed to validate these hypothesis-generating data.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin-4 and programmed death ligand-1 (PD-L1) has been reported in BCDD. Importantly, nectin-4 expression in bladder cancer is associated with response to enfortumab vedotin, and PD-L1 expression is associated with responses to immune checkpoint inhibitors (ICIs).
METHODS
METHODS
The authors conducted a retrospective review identifying 117 patients with advanced or metastatic BCDD who were treated at Winship Cancer Institute from 2011 to 2021. They performed immunohistochemistry staining for nectin-4 and PD-L1 expression by histologic subtype as well as genomic analysis of these patients, including RNA sequencing, whole-exome sequencing, and fusion detection analysis as well as a subgroup genomic analysis of patients with BCDD who received ICIs.
RESULTS
RESULTS
The results indicated that nectin-4 expression was highest in the groups who had the squamous and plasmacytoid subtypes, whereas the group that had the sarcomatoid subtype (70.8%) had the highest proportion of PD-L1-positive patients. Genomic analysis yielded several key findings, including a 50% RB1 mutation rate in patients who had small cell BCDD, targetable PIK3CA mutations across multiple subtypes of BCDD, and significantly higher expression of TEC in responders to ICIs.
CONCLUSIONS
CONCLUSIONS
In this study, the authors identified clinically relevant data on nectin-4 and PD-L1 expression in patients with rare bladder tumors. They also identified several novel findings in the genomic analysis that highlight the role of precision medicine in this population of patients. Larger, prospective studies are needed to validate these hypothesis-generating data.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : P30CA138292
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIH HHS
ID : S10 OD026799
Pays : United States
Informations de copyright
© 2024 American Cancer Society.
Références
American Cancer Society. Cancer Facts & Figures 2023. American Cancer Society; 2023.
Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6 suppl 4):S193‐S198. doi:10.5489/cuaj.1195
Nogueira LM, Yip W, Assel MJ, et al. Survival impact of variant histology diagnosis in upper tract urothelial carcinoma. J Urol. 2022;208(4):813‐820. doi:10.1097/JU.0000000000002799
Black AJ, Black PC. Variant histology in bladder cancer: diagnostic and clinical implications. Transl Cancer Res. 2020;9(10):6565‐6575. doi:10.21037/tcr‐20‐2169
Nakagawa R, Iwamoto H, Makino T, et al. Squamous or glandular differentiation predicts poor prognosis in pT1 urothelial carcinoma. In Vivo. 2022;36(5):2365‐2370. doi:10.21873/invivo.12968
Catarino R, Alves L, Pereira D, et al. Neoadjuvant chemotherapy for muscle‐invasive bladder cancer: does variant histology matter? Int Urol Nephrol. 2022;54(12):3163‐3169. doi:10.1007/s11255‐022‐03358‐3
Wright JL, Black PC, Brown GA, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178(6):2302‐2306; discussion 2307. doi:10.1016/j.juro.2007.08.038
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015‐1026. doi:10.1056/NEJMoa1613683
McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021;127(6):840‐849. doi:10.1002/cncr.33328
Miller NJ, Khaki AR, Diamantopoulos LN, et al. Histological subtypes and response to PD‐1/PD‐L1 blockade in advanced urothelial cancer: a retrospective study. J Urol. 2020;204(1):63‐70. doi:10.1097/JU.0000000000000761
Dietrich B, Siefker‐Radtke AO, Srinivas S, Yu EY. Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations. Am Soc Clin Oncol Educ Book. 2018;38:342‐353. doi:10.1200/EDBK_201193
Sarfaty M, Rosenberg JE. Antibody–drug conjugates in urothelial carcinomas. Curr Oncol Rep. 2020;22(2):13. doi:10.1007/s11912‐020‐0879‐y
Bednova O, Leyton JV. Targeted molecular therapeutics for bladder cancer—a new option beyond the mixed fortunes of immune checkpoint inhibitors? Int J Mol Sci. 2020;21(19):7268. doi:10.3390/ijms21197268
Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY‐U‐01: a phase II open‐label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum‐based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474‐2485. doi:10.1200/JCO.20.03489
Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti‐programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592‐2600. doi:10.1200/JCO.19.01140
Challita‐Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody–drug conjugate targeting nectin‐4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003‐3013. doi:10.1158/0008‐5472.CAN‐15‐1313
US Food and Drug Administration (FDA). FDA grants accelerated approval with enfortumab vedotin‐ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. Accessed June 23, 2023. https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐accelerated‐approval‐enfortumab‐vedotin‐ejfv‐pembrolizumab‐locally‐advanced‐or‐metastatic
World Health Organization (WHO) Classification of Tumours Editorial Board. Urinary and Male Genital Tumors. WHO Classification of Tumours. 5th ed. Volume 8. WHO/International Agency for Research on Cancer; 2022.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106‐119. doi:10.1016/j.eururo.2016.02.028
O'Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours—towards common understanding and reasonable expectations. Lancet Oncol. 2017;18(7):849‐851. doi:10.1016/S1470‐2045(17)30438‐2
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor‐node‐metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560‐569. doi:10.1016/j.eururo.2017.12.018
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA‐seq aligner. Bioinformatics. 2013;29(1):15‐21. doi:10.1093/bioinformatics/bts635
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059‐014‐0550‐8
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417‐425. doi:10.1016/j.cels.2015.12.004
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular Signatures Database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739‐1740. doi:10.1093/bioinformatics/btr260
Sanchez‐Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321‐337.e10. doi:10.1016/j.cell.2018.03.035
Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25(14):1754‐1760. doi:10.1093/bioinformatics/btp324
Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10(2). doi:10.1093/gigascience/giab008
Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequence‐quality aware, ultra‐sensitive variant caller for uncovering cell‐population heterogeneity from high‐throughput sequencing datasets. Nucleic Acids Res. 2012;40(22):11189‐11201. doi:10.1093/nar/gks918
Broad Institute. Picard Toolkit. Broad Institute; 2019. Accessed June 23, 2023. https://broadinstitute.github.io/picard/
Van der Auwera GA, O’Connor BC. Genomics in the Cloud. O’Reilly Media, Inc.; 2020.
Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling somatic SNVs and indels with Mutect2. bioRxiv. Preprint posted online December 2, 2019. doi:10.1101/861054
McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:10.1186/s13059‐016‐0974‐4
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434‐443. doi:10.1038/s41586‐020‐2308‐7
Kandoth C. mskcc/vcf2maf: vcfmaf v1.6. Memorial Sloan Kettering Cancer Center; 2020. doi:10.5281/zenodo.593251
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747‐1756. doi:10.1101/gr.239244.118
Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011. doi:10.1200/PO.17.00011
Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31(3):448‐460. doi:10.1101/gr.257246.119
Cunningham F, Allen JE, Allen J, et al. Ensembl 2022. Nucleic Acids Res. 2022;50(D1):D988‐D995. doi:10.1093/nar/gkab1049
Jang YE, Jang I, Kim S, et al. ChimerDB 4.0: an updated and expanded database of fusion genes. Nucleic Acids Res. 2020;48(D1):D817‐D824. doi:10.1093/nar/gkz1013
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315‐322. doi:10.1038/nature12965
Robertson AG, Kim J, Al‐Ahmadie H, et al. Comprehensive molecular characterization of muscle‐invasive bladder cancer. Cell. 2018;174(4):1033. doi:10.1016/j.cell.2018.07.036
The University of Texas Health Science Center at Houston (UTHealth). UTHealth Sustainable Business Model Innovation (SBMI) Directory. FusionGDB2. Fusion gene: PTK7‐DLK2 (FusionGDB2 ID:70072). UTHealth; 2023. Accessed June 8, 2023. https://compbio.uth.edu/FusionGDB2/gene_search_result.cgi?page=page&type=quick_search&quick_search=70072
Berger H, Wodarz A, Borchers A. PTK7 faces the Wnt in development and disease. Front Cell Dev Biol. 2017;5:31. doi:10.3389/fcell.2017.00031
Tomiyama E, Fujita K, Rodriguez Pena MDC, et al. Expression of nectin‐4 and PD‐L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020;21(15):5390. doi:10.3390/ijms21155390
US Food and Drug Administration (FDA). Drugs@FDA: FDA‐Approved Drugs. Accessed February 15, 2023. http://www.accessdata.fda.gov/scripts/cder/daf
Hoffman‐Censits JH, Lombardo KA, Parimi V, et al. Expression of nectin‐4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol. 2021;29(8):619‐625. doi:10.1097/PAI.0000000000000938
Fan Y, Li Q, Shen Q, et al. Head‐to‐head comparison of the expression differences of NECTIN‐4, TROP‐2, and HER2 in urothelial carcinoma and its histologic variants. Front Oncol. 2022;12:858865. doi:10.3389/fonc.2022.858865
Rodler S, Eismann L, Schlenker B, et al. Expression of nectin‐4 in variant histologies of bladder cancer and its prognostic value‐need for biomarker testing in high‐risk patients? Cancers (Basel). 2022;14(18):4411. doi:10.3390/cancers14184411
Chu CE, Sjostrom M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021;27(18):5123‐5130. doi:10.1158/1078‐0432.CCR‐20‐4175
US Food and Drug Administration (FDA). FDA Alerts Health Care Professionals and Investigators about an Efficacy Issue Identified in Clinical Trials for Some Patients in Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer with Low Expression of PD‐L1. FDA; 2018. Accessed February 12, 2023. https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐alerts‐health‐care‐professionals‐and‐oncology‐clinical‐investigators‐about‐efficacy‐issue
Morsch R, Rose M, Maurer A, et al. Therapeutic implications of PD‐L1 expression in bladder cancer with squamous differentiation. BMC Cancer. 2020;20(1):230. doi:10.1186/s12885‐020‐06727‐2
Blum KA, Gupta S, Tickoo SK, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17(12):659‐678. doi:10.1038/s41585‐020‐00382‐9
McGregor BA, McKay RR, Braun DA, et al. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. J Clin Oncol. 2020;38(1):63‐70. doi:10.1200/JCO.19.01882
Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22‐31. doi:10.1200/JCO.22.01643
Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(5):1441‐1446. doi:10.1158/1078‐0432.CCR‐05‐2173
Jin N, Keam B, Cho J, et al. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. J Clin Invest. 2021;131(22):131. doi:10.1172/JCI150335
Parimi V, Choi W, Feng M, et al. Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder. Histopathology. 2023;82(7):991‐1002. doi:10.1111/his.14883
Chang MT, Penson A, Desai NB, et al. Small‐cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965‐1973. doi:10.1158/1078‐0432.CCR‐17‐2655
Febres‐Aldana CA, Chang JC, Ptashkin R, et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb‐proficient subset. Clin Cancer Res. 2022;28(21):4702‐4713. doi:10.1158/1078‐0432.CCR‐22‐1115
Zoumpoulidou G, Alvarez‐Mendoza C, Mancusi C, et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1‐mutant osteosarcoma. Nat Commun. 2021;12(1):7064. doi:10.1038/s41467‐021‐27291‐8
Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287. doi:10.1016/j.ctrv.2021.102287
OncoKB. OncoKB Gene Database: ARID1A. Accessed June 13, 2023, https://www.oncokb.org/gene/ARID1A
Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL. Tec kinases regulate T‐lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev. 2009;228(1):93‐114. doi:10.1111/j.1600‐065X.2008.00757.x
Castelo‐Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O'Shea JJ. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023;23(12):1‐20. doi:10.1038/s41577‐023‐00877‐7
Ferrucci V, Asadzadeh F, Collina F, et al. Prune‐1 drives polarization of tumor‐associated macrophages (TAMs) within the lung metastatic niche in triple‐negative breast cancer. iScience. 2021;24(1):101938. doi:10.1016/j.isci.2020.101938